공시 • Jan 22
Arix Bioscience plc Announces Resignation of Directors Arix Bioscience plc announced that Maureen O'Connell and Isaac Kohlberg have resigned from the Arix Board with effect upon the completion of the Share Purchase. 공시 • Sep 28
Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023 Arix Bioscience plc announced resignation of Robert Lyne as Chief Executive Officer. He has decided to step down from his position to pursue a new opportunity and will leave the company by the end of 2023. Board Change • Sep 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • Sep 15
Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023 Arix Bioscience plc announced that they will report first half, 2023 results on Sep 27, 2023 New Risk • Aug 31
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Board Change • Aug 31
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Feb 09
Independent Non-Executive Chairman recently bought UK£217k worth of stock On the 6th of February, Peregrine David Euan Moncreiffe bought around 200k shares on-market at roughly UK£1.09 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£398k worth in shares. Board Change • Feb 08
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). CEO, General Counsel & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 공시 • Jan 27
Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director Arix Bioscience plc announced Dr. Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests. Reported Earnings • Aug 11
First half 2022 earnings released First half 2022 results: Net income: (up UK£38.5m from 1H 2021). Board Change • Aug 11
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Chief Executive Officer Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 공시 • Aug 11
Arix Bioscience plc Announces Board and Committee Changes Arix Bioscience plc announced the appointments of Dr. Debra Barker, Dr. Benny Soffer, and Andrew Smith as Senior Independent Director and Non-Executive Directors respectively with immediate effect. In light of these appointments which bring the Board into compliance with the UK Corporate Governance Code, Sir Michael Bunbury is resigning from the Board with immediate effect. Debra Barker will Chair the Company’s Remuneration Committee and Andrew Smith will Chair the Company’s Audit Committee. Debra Barker is a seasoned international life sciences executive with more than 25 years’ senior and board experience from start-up biotech to big pharma companies, having held a number of senior drug development, strategic and operational roles in Novartis, Roche, SmithKline Beecham and Knoll. Debra is currently Non-Executive Director of three publicly listed biotechnology companies: Destiny Pharma plc, BergenBio in Norway and most recently, CureVac AG in Germany. Debra has a Diploma in Pharmaceutical Medicine and received a MSc in Immunology from the King's College in London and a Medical Degree from the Queens’ College, Cambridge, UK. Benny Soffer, MD is Co-Founder and Chief Investment Officer of Consonance Capital Management, a healthcare-focused public equity investment management firm. He previously completed a residency in internal medicine at Yale and served in a variety of managerial roles at Yale-New Haven Hospital. Dr. Soffer is a Clinical Assistant Professor of Medicine at Weill Cornell Medicine, receiving his MD at Emory University and his MBA at Yale University. Andrew Smith is an internationally experienced chief financial officer with strong financial and operational experience in US, Swiss and UK-based biotech and pharmaceutical companies. Andrew is currently Chief Financial Officer of Santhera Pharmaceuticals, the Swiss-based speciality pharmaceutical company, having previously held a number of senior operational and financial roles in companies including Allecra Therapeutics, Sucampo Pharmaceuticals Inc., and Retroscreen Virology (Now HVIVO Ltd). He is a Fellow of the Chartered Institute of Management Accountants and a Chartered Global Management Accountant. He studied business and accounting at Liverpool John Moores University and Durham University Business School. 공시 • Aug 04
Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022 Arix Bioscience plc announced that they will report first half, 2022 results on Aug 10, 2022 공시 • May 04
Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022 Arix Bioscience plc announced that they will report fiscal year 2021 results on May 05, 2022 Board Change • Apr 02
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of Scientific Advisory Board K. Patel is the most experienced director on the board, commencing their role in 2020. Senior Independent Director Michael Bunbury was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 
